2/9
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/4
08:29 am
cccc
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Medium
Report
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
2/4
07:00 am
cccc
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2/2
09:05 pm
cccc
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory [Yahoo! Finance]
Medium
Report
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory [Yahoo! Finance]
1/26
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/21
08:40 am
cccc
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel [Yahoo! Finance]
Low
Report
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel [Yahoo! Finance]
1/15
03:29 pm
cccc
Clinical trial results drove insider trading: SEC [Investment Executive - News]
Low
Report
Clinical trial results drove insider trading: SEC [Investment Executive - News]
1/14
07:00 am
cccc
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Low
Report
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
12/17
07:18 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.
High
Report
C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.
12/2
08:04 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
12/2
07:10 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
11/26
06:33 am
cccc
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
Medium
Report
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
11/25
07:00 am
cccc
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
11/21
05:17 pm
cccc
C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]
Medium
Report
C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]